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Summary Epidermal growth factor (EGF) receptor expression in 31 primary human bladder tumours was
quantitated using both structural and functional assays and the EGF receptor gene in the same tumours was
analyzed by Southern blot analysis. Immunocytochemical studies using the EGFR1 monoclonal antibody
(Mab) showed a significant correlation between EGF receptor levels and the stage and grade of the tumours.
Autophosphorylation assays employed to evaluate the receptor's tyrosine kinase activity gave results which in
general were consistent with the immunocytochemical data. Using internally controlled immunocytochemical
studies with two Mabs and Southern blot analysis of DNA isolated from the tumours, no evidence was
obtained for the production of truncated receptors similar to those encoded by the v-erb-B oncogene. Gene
amplification was not found in any of the superficial tumours, but one invasive tumour with high EGF
receptor expression had an 8-10 fold amplification of the EGF receptor gene. The EGF receptor isolated
from this tumour showed a normal pattern of tyrosine phosphorylation at all three major auto-
phosphorylation sites. Our detailed study is consistent with the correlation previously found between EGF
receptor expression and stage and grade of bladder tumours, and suggests that at this level of analysis EGF
receptors in bladder tumours are not abnormal in structure or size, autophosphorylation activity, or gene
structure.
The receptor for EGF is a 175,000 mol. wt membrane
protein which consists of an extracellular EGF-binding
domain, a short hydrophobic transmembrane segment, and
an intracellular domain which possesses a ligand stimulated
tyrosine kinase activity (Carpenter, 1983; Downward et al.,
1984a). The receptor can phosphorylate a number of protein
substrates, in addition to mediating autophosphorylation of
three tyrosine residues located close to its own carboxy
terminus (Downward et al., 1984b; Gullick et al., 1985). The
role of the tyrosine kinase activity in signal transduction is
not clear, but it is presently the only known ligand-
stimulated activity of the receptor protein and therefore is
likely to be involved in the transmembrane signaling process.
Study of the structure and function of the EGF receptor
in tumours was stimulated by the observation that the v-erb-
B oncogene of avian erythroblastosis virus, which can cause
erythroblastosis and sarcomas in infected chickens, is derived
from the chicken EGF receptor gene. (Downward et al.,
1984a; Olofsson et al., 1986). The transforming protein
produced from the v-erb-B oncogene is a doubly truncated
chicken EGF receptor which lacks virtually the entire extra-
cellular ligand binding domain as well as the most C-
terminal autophosphorylation site (Downward et al.,
1984a,b;). It has been suggested that the loss of the ligand
binding domain of the receptor may leave the tyrosine kinase
of v-erb-B in a constitutively active form (Gilmore et al.,
1985; Kris et al., 1985). Since the EGF receptor kinase
catalyses the transfer of phosphate groups to tyrosine
residues of substrate proteins, it would seem likely that the
amount of tyrosine kinase activity would be important in
influencing the growth rate of cells. For instance, an
abnormal EGF receptor with increased tyrosine kinase
activity might cause rapid cell division. We therefore isolated
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EGF receptors from the tumour specimens and analyzed
their enzyme activity by their ability to become radioactively
labeled with 32P by autophosphorylation.
The loss of the most C-terminal autophosphorylation site,
the major site used in vivo, might also be an important
structural change leading to functional abnormalities of the
v-erb-B oncogene protein (Downward et al., 1984b). Other
oncogene proteins, such as those of v-fms (Coussens et al.,
1986) and v-src (Takeya et al., 1983), also differ from their
proto-oncogene counterparts by the loss of a C-terminal
tyrosine. Phosphorylation of a tyrosine in the C-terminal
area of the normal cellular counterpart of these proteins may
play a role in inhibiting receptor kinase activity. We
therefore examined the EGF receptor from one bladder
tumour with high levels of EGF receptors (high levels are
required to do the study) to see both whether this site was
present in the protein and whether it was utilized normally
as a site of autophosphorylation.
Although abnormalities in the structure of EGF receptor
proteins have not yet been found in human tumours, high
levels of EGF receptor expression have been identified in
certain types of tumours, sometimes associated with
amplification of the EGF receptor gene. Immunocyto-
chemical studies have shown that the basal cell layer of
normal squamous cell epithelia expresses easily detectable
levels of EGF receptors (Gusterson et al., 1984). Squamous
cell carcinomas from various primary sites (Hendler &
Ozanne, 1984; Cowley et al., 1984) have been found to
express relatively high levels of EGF receptors, as have some
gliomas (Libermann et al., 1984a), gynaecological tumours
(Gullick et al., 1986), breast tumours (Fitzpatrick et al.,
1984; Perez et al., 1984; Sainsbury et al., 1985), and
sarcomas (Gusterson et al., 1985).
Some squamous cell carcinoma cell lines with high EGF
receptor expression have amplification of the EGF receptor
gene (Merlino et al., 1984; Merlino et al., 1985; Yamamoto
et al., 1986; Ozanne et al., 1986). These include the well
studied vulval carcinoma cell line A431 (Merlino et al.,
1984). Amplification has also been described in a breast
carcinoma cell line (Filmus et al., 1985) and in primary
specimens of some gliomas (Libermann et al., 1984b) and
squamous cell carcinomas (Ozanne et al., 1985; Ozanne et
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al., 1986; Hunts et al., 1985). Although some bladder
tumours have been reported to have high levels of EGF
receptor protein expression (Neal et al., 1985; Gusterson et
al., 1984), the structure of the EGF receptor gene in bladder
tumours has not been studied.
Since a previous immunohistochemical study suggested
that EGF receptors were found significantly more often in
invasive and poorly differentiated tumours than in superficial
and moderately differentiated tumours (Neal et al., 1985), we
undertook the present study to explore in greater depth the
role of EGF receptors in bladder tumours of various stages
and grades by evaluating the levels, structure, and function
of EGF receptor protein and the copy number and structure
of the EGF receptor gene.
Materials and methods
Fresh tumour samples were obtained from newly diagnosed
patients with transitional carcinoma of the bladder. The
tumours were staged clinically and pathologically by the
urology and pathology departments of Freeman Hospital,
Newcastle Upon Tyne. Dr M. Bennett of the Pathology
Department carried out histological grading on paraffin
sections of the tumours according to standard criteria
(American Joint Committee on Cancer, 1983). Superficial
tumours were classified as those not invading bladder muscle
(Ta,TI), and invasive tumours as those with muscle invasion
identified pathologically (T2, T3) according to standard
criteria (American Joint Committee on Cancer, 1983).
Samples of the tumours were frozen in isopentane cooled to
-180°C with liquid nitrogen and stored in liquid nitrogen.
All laboratory studies were performed without knowledge of
stage or grade of the tumours. Fisher's exact test was used
for statistical analysis.
The anti-EGF receptor antibodies for frozen section
immunocytochemical studies were EGFR1, a Mab to the
extracellular domain (Waterfield et al., 1982) used at a
concentration of 0.01 mgml-1, and F4, a Mab to the
intracellular domain (Gullick et al., 1986) used at a
concentration of 0.05mgml-1. These antibodies to different
domains of the receptor were used to screen for truncated
EGF receptor species analagous to the v-erb-B protein.
Alkaline phosphatase/anti-alkaline phosphatase (APAAP)
complexes were used in an unlabeled antibody bridge
technique as described previously (Cordell et al., 1984). A
control tissue, squamous cell epithelium from the oral
mucosa, was used to ensure that the same intensity of
staining was achieved with both Mabs. The control tissue
was also used to standardize the level of antibody staining,
the staining of the basal cells of the oral mucosal epithelium
being defined as weak.
EGF receptors were isolated from frozen samples of
bladder tumours by immunoprecipitation and their ability to
autophosphorylate assayed as described previously (Gullick
et al., 1986). Using methods described in detail elsewhere
(Downward et al., 1984b), EGF receptor protein was isolated
from one of the tumours and subjected to tryptic
phosphopeptide mapping by HPLC to determine whether all
three sites of autophosphorylation were present and utilized
in receptor catalyzed phosphorylation.
Southern blot analysis was performed to ascertain whether
amplification or rearrangement of the EGF receptor gene
was present (Maniatis et al., 1982). The cDNA probe used in
Southern blot analysis, 64.1, corresponded to most of the
extracellular domain, all of the transmembrane region, and a
short sequence of the intracellular domain. (Haley et al.,
1987).
Results
Immunocytochemistry
Thirty-one tumours were evaluated by immunocytochemistry
for their levels of EGF receptor protein expression using the
two antibodies to the EGF receptor. Six samples of normal
bladder or ureter urothelium showed very weak staining
which was confined to the basal layer of the urothelium. We
graded as positive those tumours that expressed EGF
receptor levels that were higher than that seen in normal
urothelium; that is, weak, moderate or strong. Weak staining
was further defined as being equal to the staining of the cells
in the basal layer of the oral mucosal control tissue.
Heterogeneity of staining was observed in 6 of the 11
positive tumours. This took the form of weaker staining of
the 20-30% of the cells comprising the inside of masses of
tumour cells. Otherwise, the staining of tumour cells was
virtually homogenous.
The immunocytochemical data (Table I) shows that there
was little disparity in the results obtained with the
monoclonal antibodies to the extracellular domain (EGFR1)
and the cytoplasmic region (F4) in any individual tumour
specimen. In particular, there were no tumours with
significant F4 staining and negative staining with EGFR1,
which might have indicated the presence of truncated
receptors. Our results using Mab EGFR1 showed a
significant correlation between tumours that were positive
for EGF receptors and invasive stage (P=0.01) and poor
differentiation (P=0.005) (Table II). The data using the F4
Mab shows a similar trend that did not reach statistical
significance in the small group of tumours studied (Table II).
Table I Immunohistochemistry and autophosphorylation data
arranged according to tumour stage
Immunocyto-
chemistry
Bladder Autophos-
specimen Stage Grade EGFRI F4 phorylation
Superficial
1 Ta Well 1 1 +
3 Ta Mod 1 2 +
7 Ta Mod 1 2 + +
15 Ta Mod 1 1 + +
19 Ta Mod 0. 0
22 Ta Mod 0 0 ND
24 Ta Mod 1 0 +
29 Ta Poor 0 0
8 Ti Poor 1 2 +
17 Ti Mod 0 0 -
18 Ti Mod 0 0 +
25 Ti Mod 0 1 -
26 Ti Poor 1 0 +
27 Ti Mod 1 1 +
Invasive
23 T2 Poor 2 2 ND
30 T2 Mod 1 0 +
31 T2 Poor 3 3 +
2 T3 Poor 2 2 + +
4 T3 Poor 2 2 + +
5 T3 Poor 0 0
6 T3 Poor 3 2 + +
9 T3 Poor 0 0
10 T3 Poor 2 2 +
11 T3 Poor 4 4 + + +
12 T3 Poor 0 0 ND
13 T3 Poor 0 0 +
14 T3 Poor 1 0
16 T3 Poor 2 1 +
20 T3 Mod 4 4 + +
21 T3 Poor 2 0 +
28 T3 Poor 3 1 + +
ND =not done due to lack ofmaterial.
Scale for immunocytochemistry data:
Negative 0=no staining
1=very weak staining
Positive 2=weak staining
3=moderate staining
4=strong stainingEGF RECEPTORS IN BLADDER TUMOURS 535
Table II Immunocytochemistry results summarized according to
bladder tumour stage and grade Bi1
EGFRI F4
Negative Positive Negative Positive
Grade
Moderate 12 1 10 3
Poor 8 10 10 8
Stage
Superficial 14 0 11 3
Invasive 6 11 9 8
Autophosphorylation
Representative results obtained from immunoprecipitation
and autophosphorylation of 5 of the bladder tumours are
shown in Figure 1 and the results from all 28 specimens
examined are given in Table I. The level of auto-
phosphorylation observed generally correlated well with the
amount of receptor protein accessed by immuno-
cytochemistry but did not yield a statistically significant
correlation with stage or grade of the tumours. It is possible
that minor differences in tissue preservation may have had a
greater effect on kinase activity than on immunologic
detection of the EGF receptor. Different percentages of
tumour and stromal tissue in the samples may also have
contributed to the variability of the results. One tumour
specimen, no. 11 demonstrated EGF receptor auto-
phosphorylation of much greater magnitude than any other
tumour (Figure 1, track 5).
Phosphopeptide mapping
Phosphopeptide mapping of tryptic digests of purified,32P-
labelled receptor was carried out on material from the
tumour with the highest EGF receptor expression (bladder
tumour no. 11) and on receptor isolated from A431 cells.
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Figure 1 Immunoprecipitation and autophosphorylation of
EGF receptor from extracts of human tumours. Tracks 1-5 are
from tumours 7-11 respectively. Autoradiograph exposure times
using Kodak XAR5 film were 5 h for lanes 1-4 and 30min for
lane 5.
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Figure 2 Phosphopeptide mapping of EGF receptor tryptic
digests. Bll indicates bladder tumour no. 11. A431 indicates the
phosphopeptide map of A431 cells used as a control.
They showed the same pattern of labeled peptides with
utilization of all three of the previously identified auto-
phosphorylation sites to the same extent (Figure 2). The
phosphopeptide map of A431 cells is identical to that of
EGF receptors from a normal tissue (placenta) and thus
served as a control (Downward et al., 1984a).
EGF receptor gene analysis
The EGF receptor gene was analyzed by Southern blotting
using DNA isolated from 29 tumours (in one case an
inadequate amount of DNA was obtained, and one other
specimen gave only degraded DNA despite repeated
attempts at isolation). The EGF receptor gene was found to
be amplified -8-10 times without apparent rearrangement
in bladder tumour no. 11IFigure 3, lane 11). This tumour
was previously shown to have a high level of receptor
expression by both immunocytochemical and auto-
phosphorylation studies. In all other cases, the gene was
present in a single copy without evidence of rearrangement.
Discussion
Urine bathing the bladder mucosa contains epidermal
growth factor (EGF) in ngml-I concentrations which are
substantially higher than the pgml-1 concentrations usually
found in serum (Oka & Orth, 1983; Mattila et al., 1986).
An abnormal increase in the number of EGF receptors on
cells in this environment might lead to an increased
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Figure 3 Analysis of EGF receptor gene sequences by Southern
blotting. End-labelled molecular weight markers are at far left.
Track labelled A was loaded with 2.5pg A431 cell DNA and
track labelled P with lOpg placental DNA. Tracks 1-12
represent lOg DNA from tumours 1-12 respectively. Tumour 9
gave only degraded DNA on several attempts at DNA isolation.
The autoradiograph was exposed for 48 h at -70'C using
Kodak XAR5 film.
responsiveness to EGF and to stimulation of growth.
Alternatively, the production of mutant receptors with an
enhanced response to EGF, or with no response to EGF,
could result in profound abnormalities in the control of
urothelial cell growth. There is as yet no direct evidence that
implicates EGF in urine as a critical element for the growth
of bladder tumours, but the higher EGF levels found there
suggested that the study of EGF receptors in bladder
tumours might be productive.
Recent literature has suggested that prognostic
information may be derived from the study of proto-
oncogenes in some tumours. For example, N-myc gene
amplification in neuroblastomas (Seeger et al., 1985; Brodeur
et al., 1986), ras expression in prostate carcinomas (Viola et
al., 1986), and amplification of the EGF receptor related
HER-2 gene in breast carcinomas (Slamon et al., 1987) all
have been shown to have prognostic implications for patients
with those tumours. A marker which could similarly predict
the behaviour of bladder tumours would be very valuable to
oncologists and urologists. Neal et al. (1985) suggested that
EGF receptor expression was related to the pathologic
characteristics of malignant bladder tumours and our data
are consistent with that finding.
In this study the immunocytochemistry data using the
EGFR1 Mab, the same antibody used by Neal et al. (1985),
showed a statistically significant correlation between positive
tumours and bladder carcinoma stage and grade. Statistically
significant correlations with tumour stage and grade were
not seen using the F4 Mab, although a trend was clearly
present. The affinity of the F4 Mab for the EGF receptor in
solution is -5-10 fold lower than the EGFR1 Mab and thus
it was used at five times the concentration of the EGFR1
Mab to obtain staining of the same intensity from a control
oral mucosal tissue. In future studies we would recommend
using the EGFR1 Mab because of its greater sensitivity.
This study was different from that of Neal et al. (1985) in
that a more sensitive immunocytochemical technique
(APAAP) was used. This resulted in very weak staining of
normal bladder mucosa and allowed us to grade as positive
only those tumours that were more strongly stained than the
normal mucosa. The previous study used an indirect
immunocytochemistry technique and found normal bladder
mucosa to be negative. Furthermore we think that the use of
one control tissue (oral mucosa) throughout the study re-
duced the subjectivity inherent in comparing tumours stained
on different days.
The F4 Mab was principally employed to determine
whether bladder tumours expressed a large population of
truncated EGF receptors analogous to the v-erb-B protein.
This was not found to be the case since differences in
staining of individual tumours were small (Table I). The
presence of low concentrations of truncated receptors cannot
be totally excluded, but since EGF receptor gene structure
was normal on Southern blots this is unlikely.
The autophosphorylation studies demonstrated that the
EGF receptor protein identified immunologically was func-
tional at least in its ability to mediate autophosphorylation,
and that abnormal sized EGF receptors were not produced
in the tumours. The percentage of tumours with demon-
strable autophosphorylation activity was not appreciably
different in tumours of advanced stage and grade than in
those which were histologically less aggressive, although
tumours with higher levels of autophosphorylation activity
were more common in the poorly differentiated or invasive
tumour groupings. The autophosphorylation assay in our
hands was not as precise a technique as immunocyto-
chemistry and this may explain differences in the results
obtained with the two methods. In the one case where the
bladder tumour was rich enough in receptor protein to be
analyzed, the EGF receptors were shown to utilize the three
major autophosphorylation sites normally.
Receptor gene amplification was found in only one
tumour which also had very high levels of EGF receptor
protein. Major deletions, truncation or rearrangement were
not seen in the area of the gene probed. The gene structure
of another proto-oncogene, the c-H-ras-1 gene, which has
been shown by transfection assays to be present as a
transforming oncogene in some bladder carcinoma cell lines
and primary tumours (Fujita et al., 1984), has also been
studied in bladder tumours. Amplification and rearrange-
ment of this gene has been reported in one case of squamous
cell carcinoma of the bladder (Hayashi et al., 1983).
However a study of 15 unselected bladder tumours found no
amplification or rearrangement of the c-H-ras-1 gene, sug-
gesting that, just as in the case of the EGF receptor gene, its
amplification is not a common event (Malone et al., 1985).
Point mutations such as those shown to activate the ras
(Sukumar et al., 1983) and neu (Bergmann et al., 1986)
oncogenes would not be detected by the methods used in this
study and thus we cannot conclude that the EGF receptor
gene in these tumours is entirely normal. Some recent reports
(e.g. Reidel et al., 1987) suggest that there may be as yet
unidentified point mutations in the v-erb-B oncogene that
are important to its function. If future work identifies
specific amino acid differences between the chicken EGF
receptor and v-erb-B, this may provide the means for further
evaluation of the EGF receptors in bladder tumours which,
from this analysis, appear to be normal in structure and
function.
Further work is needed to determine if EGF receptor
expression in bladder tumours is directly related to prog-
nosis. We have planned prospective studies utilizing immuno-
cytochemistry with Mab EGFR1 to evaluate recurrence rates
and death rates in patients with tumours of different stage,
grade, and levels of EGF receptor expression.
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